Eric Lawitz1, Mark S Sulkowski2, Reem Ghalib3, Maribel Rodriguez-Torres4, Zobair M Younossi5, Ana Corregidor6, Edwin DeJesus7, Brian Pearlman8, Mordechai Rabinovitz9, Norman Gitlin10, Joseph K Lim11, Paul J Pockros12, John D Scott13, Bart Fevery14, Tom Lambrecht15, Sivi Ouwerkerk-Mahadevan14, Katleen Callewaert14, William T Symonds16, Gaston Picchio17, Karen L Lindsay17, Maria Beumont14, Ira M Jacobson18. 1. Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA. Electronic address: lawitz@txliver.com. 2. Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Texas Clinical Research Institute, Arlington, TX, USA. 4. Fundación de Investigación, San Juan, PR, USA. 5. Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA. 6. Borland-Groover Clinic, Jacksonville, FL, USA. 7. Orlando Immunology Center, Orlando, FL, USA. 8. Atlanta Medical Center, Atlanta, GA, USA. 9. University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 10. Atlanta Gastroenterology Association, Atlanta, GA, USA. 11. Yale Liver Center and Yale University School of Medicine, New Haven, CT, USA. 12. Scripps Clinic, La Jolla, CA, USA. 13. Harborview Medical Center, Seattle, WA, USA. 14. Janssen Research & Development, Beerse, Belgium. 15. Novellas Healthcare, Zellik, Belgium. 16. Gilead Sciences Inc, Foster City, CA, USA. 17. Janssen Research & Development, Titusville, NJ, USA. 18. Weill Cornell Medical College, New York, NY, USA.
Abstract
BACKGROUND:Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of combined simeprevir and sofosbuvir. METHODS: We enrolled patients with chronic HCV genotype 1 infections who had previously not responded topegylated interferon (peginterferon) and ribavirinor were treatment naive. Patients were randomly assigned in a 2:1:2:1 ratio to receive 150 mg simeprevir and 400 mg sofosbuvir daily for 24 weeks with (group 1) or without (group 2) ribavirin or for 12 weeks with (group 3) or without (group 4) ribavirin, in two cohorts: previous non-responders with METAVIR scores F0-F2 (cohort 1) and previous non-responders and treatment-naive patients with METAVIR scores F3-F4 (cohort 2). The primary endpoint was sustained virological response 12 weeks after stopping treatment (SVR12). Analysis was done by intention to treat. Safety data from cohorts 1 and 2 were pooled for analysis. This study is registered with ClinicalTrials.gov, number NCT01466790. FINDINGS:168 patients were enrolled and randomised, and 167 started treatment (n=80 in cohort 1 and n=87 in cohort 2). SVR12 was achieved in 154 (92%) patients (n=72 [90%, 95% CI 81-96] in cohort 1 and n=82 [94%, 87-98] in cohort 2). The most common adverse events in the pooled groups were fatigue (n=52 [31%]), headache (n=33 [20%]), and nausea (n=26 [16%]). Grade 4 adverse events were seen in one (2%) of 54 patients in each of groups 1 and 3 and in three (10%) of 31 patients in group 2, whereas grade 3-4 events were reported in less than 5% of all patients, except increased blood amylase concentration. Serious adverse events were seen in four (2%) patients, all in groups 1 and 2. Four (2%) patients discontinued all study treatment because of adverse events, three before week 12. INTERPRETATION:Combined simeprevir and sofosbuvir was efficacious and well tolerated. FUNDING: Janssen.
RCT Entities:
BACKGROUND: Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of combined simeprevir and sofosbuvir. METHODS: We enrolled patients with chronic HCV genotype 1 infections who had previously not responded to pegylated interferon (peginterferon) and ribavirin or were treatment naive. Patients were randomly assigned in a 2:1:2:1 ratio to receive 150 mg simeprevir and 400 mg sofosbuvir daily for 24 weeks with (group 1) or without (group 2) ribavirin or for 12 weeks with (group 3) or without (group 4) ribavirin, in two cohorts: previous non-responders with METAVIR scores F0-F2 (cohort 1) and previous non-responders and treatment-naive patients with METAVIR scores F3-F4 (cohort 2). The primary endpoint was sustained virological response 12 weeks after stopping treatment (SVR12). Analysis was done by intention to treat. Safety data from cohorts 1 and 2 were pooled for analysis. This study is registered with ClinicalTrials.gov, number NCT01466790. FINDINGS: 168 patients were enrolled and randomised, and 167 started treatment (n=80 in cohort 1 and n=87 in cohort 2). SVR12 was achieved in 154 (92%) patients (n=72 [90%, 95% CI 81-96] in cohort 1 and n=82 [94%, 87-98] in cohort 2). The most common adverse events in the pooled groups were fatigue (n=52 [31%]), headache (n=33 [20%]), and nausea (n=26 [16%]). Grade 4 adverse events were seen in one (2%) of 54 patients in each of groups 1 and 3 and in three (10%) of 31 patients in group 2, whereas grade 3-4 events were reported in less than 5% of all patients, except increased blood amylase concentration. Serious adverse events were seen in four (2%) patients, all in groups 1 and 2. Four (2%) patients discontinued all study treatment because of adverse events, three before week 12. INTERPRETATION: Combined simeprevir and sofosbuvir was efficacious and well tolerated. FUNDING: Janssen.
Authors: Meghan E Sise; Allyson K Bloom; Jessica Wisocky; Ming V Lin; Jenna L Gustafson; Andrew L Lundquist; David Steele; Michael Thiim; Winfred W Williams; Nikroo Hashemi; Arthur Y Kim; Ravi Thadhani; Raymond T Chung Journal: Hepatology Date: 2015-12-11 Impact factor: 17.425
Authors: Channa R Jayasekera; Ryan B Perumpail; David T Chao; Edward A Pham; Avin Aggarwal; Robert J Wong; Aijaz Ahmed Journal: Dig Dis Sci Date: 2015-12 Impact factor: 3.199
Authors: Cindy J Bednasz; Joshua R Sawyer; Anthony Martinez; Patrick G Rose; Samantha S Sithole; Holly R Hamilton; Farzia S Kaufman; Charles S Venuto; Qing Ma; Andrew Talal; Gene D Morse Journal: Future Virol Date: 2015 Impact factor: 1.831
Authors: Mark H Kuniholm; Molly Jung; Julia Del Amo; Gregory A Talavera; Bharat Thyagarajan; Ronald C Hershow; Oriana M Damas; Robert C Kaplan Journal: J Immigr Minor Health Date: 2016-12